Novo Nordisk A/S $NVO Stock Holdings Increased by Vise Technologies Inc.

Vise Technologies Inc. grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 26.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,350 shares of the company’s stock after buying an additional 14,915 shares during the period. Vise Technologies Inc.’s holdings in Novo Nordisk A/S were worth $2,667,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. Arrowstreet Capital Limited Partnership purchased a new position in Novo Nordisk A/S during the 1st quarter valued at about $287,660,000. Maverick Capital Ltd. purchased a new stake in Novo Nordisk A/S in the first quarter worth about $76,444,000. Public Employees Retirement System of Ohio bought a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $27,802,000. CORDA Investment Management LLC. bought a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $15,322,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novo Nordisk A/S by 2,414.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock valued at $14,280,000 after purchasing an additional 286,034 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $42.21 on Thursday. The firm has a market cap of $188.45 billion, a P/E ratio of 10.32, a PEG ratio of 1.36 and a beta of 0.70. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a 50 day moving average of $40.84 and a 200 day moving average of $44.07.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. As a group, research analysts expect that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on NVO. DZ Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Cfra cut Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective for the company. in a research note on Tuesday, September 22nd. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Finally, UBS Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus target price of $59.44.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat analysts’ estimates for third-quarter earnings and revenue. Adjusted sales rose 4%, adjusted operating profit increased 27%, and obesity-drug sales climbed 22%. The company raised its full-year 2026 sales and operating-profit outlook. Reuters report on earnings and guidance
• Positive Sentiment: Wegovy pill sales exceeded Wall Street expectations, giving Novo a promising early foothold in the oral weight-loss drug market and helping drive the outlook upgrade. CEO Mike Doustdar said the launch had exceeded expectations. BioPharma Dive report on Wegovy pill sales
• Neutral Sentiment: Doustdar declined to provide 2027 guidance, leaving investors without a clear view of growth beyond this year. Novo’s CFO Karsten Munk Knudsen is also expected to leave the company. Article on earnings, outlook and 2027 guidance
• Negative Sentiment: Pricing pressure and weaker diabetes performance remain risks to growth, while impairment charges weighed on reported operating profit. Competition from Eli Lilly also remains a concern, especially as the oral obesity-drug market develops. Zacks analysis of earnings and risks

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.